
    
      The primary study objective is to compare HBV DNA suppression to levels below the limit of
      detection (<400 copies/ml) by week 48 in each treatment group. Virological and clinical
      anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients with
      HIV/HBV co-infection.
    
  